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Abstract 
Purpose:   
 To compare retinal microvascular function in healthy individuals with and without a positive FH 
of CVD.  
Methods:  
Retinal vessel reactivity was assessed by means of dynamic retinal vessel analysis (DVA) in 38 
healthy subjects aged between 30 and 66 years with a positive family history (FH) of 
cardiovascular disease (CVD), and 37 age- and gender-matched control subjects. Other 
assessments included blood pressure (BP) profiles, blood glucose and lipid metabolism markers, 
Framingham risk scores (FRS), carotid intima-media thickness (c-IMT) and brachial flow-
mediated dilation (FMD).  
Results:  
FH positive subjects showed decreased retinal arterial baseline diameter fluctuation, dilation 
amplitude, percent dilation, and overall constriction response slope (p = 0.001; p = 0.015; p = 
0.001; and p < 0.001, respectively), and increased percent constriction (p = 0.008). On the 
venous side, baseline corrected flicker response and dilation response slope were decreased in 
the FH positive group (p = 0.009 and p = 0.010, respectively). There were no significant 
differences between groups in c-IMT scores or FMD parameters (all p > 0.05). The arterial 
MC% correlated negatively with decreased HDL-c (r = -0.52, p = 0.002 in only FH positive 
group. 
Conclusion:  
Although macrovascular function is preserved in individuals with FH positive for CVD but with 
low FRS, there are, however, functional impairments at the retinal microvascular level that 
correlate with established plasma markers for cardiovascular risk. 
Key words: Vascular function, dynamic retinal vessel analysis, family history, cardiovascular 
risk 
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INTRODUCTION 
It has been previously documented that a positive family history (FH) of cardiovascular disease 
(CVD) increases the risk for various circulatory pathologies (Myers et al.1990; Shea et al. 1984; 
Khaleghi et al. 2014; Philips et al. 2007). In addition, as FH encompasses a complex interaction 
between environmental and genetic variables, it represents a good way of measuring the 
inherited component of any disease, including CVD (Banerjee 2012). Several risk scores, 
including the Prospective Cardiovascular Mὒnster (PROCAM), QRISK and Scottish 
Intercollegiate Guidelines Network (ASSIGN) include various components of FH of CVD but 
due to lack of standardisation, this information is inconsistently used as a risk predictor in 
clinical practice. Moreover, these scores have been shown to either over- or underestimate the 
actual risk in a large number of individuals (Vasan 2006; Cohn 2013; Koenig 2007).    
Consequently, the need arose for developing other simple tests that are quick and sensitive 
enough to detect subclinical disease (Wang 2011; Helfand et al.2011; Ge & Wang 2012) For this 
purpose, one of the most promising avenues is assessing endothelial dysfunction (ED), an entity 
in which the homeostatic functions of the endothelium are impaired, resulting in abnormal 
vascular tone, blood flow, immune cell and platelet activity/adhesion (Moncada et al. 1991). 
 
It is well known that ED represents an early predictor of subsequent cardiovascular events or 
mortality. Moreover, signs of ED may be apparent even in people without an overt disease but 
with a FH of cardiovascular pathology (Celermajer et al.1994; Vita et al 1990; de Jongh et 
al.2002). Assessing this parameter is, therefore, important for predicting CVD risk and 
employing all the necessary preventive and therapeutic measures to decrease morbidity and 
mortality. Traditionally, the presence of ED is assessed by techniques such as ultrasound flow-
mediated dilation (FMD), pulse wave analysis (PWA), plethysmography, and iontophoresis (Ray 
et al. 2014). These tests however, can be complex, time-consuming, and are performed only in 
highly specialized services. Dynamic retinal vessel analysis (DVA) represents a non-invasive 
way of evaluating VED at the retinal microvascular level (Pemp et al. 2009; Dorner et al.2003) 
and its usefulness in measuring early changes that signal risk for future cardiovascular 
pathologies in individuals with or without overt disease has already been proven (Pemp et al. 
2009; Reimann et al.2009; Kotliar et al. 2011). In addition, it can also detect signs of ED at the 
retinal microvascular level in the presence of more subtle risk factors for CVD such as ageing 
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(Seshadri et al. 2015), ethnicity (Patel et al.2011), altered lipid and oxidative stress marker levels 
(Seshadri et al. 2015), and impaired glucose tolerance (Patel et al.2012).  
 
There is still a debate if ED can be considered an independent risk factor for CVD in low-risk 
individuals (Cardona et al. 2015) Therefore, it is possible that ED’s capabilities to predict risk for 
CVD can be increased by association with other traditional risk factors, such as FH. Therefore, 
this study investigates if individuals with low personal risk (FRS <= 10%) but with FH of CVD 
exhibit early signs of vascular dysfunction at microvascular levels when compared to those 
without FH. In addition, the relationship between these changes and the circulatory markers for 
CVD risk is also analysed.  
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METHODS 
Study participants 
Community-dwelling volunteers (aged above 18 years) were recruited through local 
advertisements at the Vascular Research Laboratory and Health Clinics at Aston University 
(Birmingham, UK). Ethical approval for this study was received from Aston University’s ethics 
committee and written informed consent was received from all participants prior to study 
enrolment. All study procedures were
 
designed and conducted in accordance with the tenets of 
the Declaration
 
of Helsinki.  
Study participants were considered for inclusion on the basis of self-declared FH of CVD (to 
include coronary artery disease, heart failure, arrhythmia, and vascular disease) in a first-degree 
relative, identified by way of self-report questionnaire.  
Study exclusion criteria were defined as subject history or current diagnosis of cardiovascular or 
cerebrovascular disease including coronary artery disease, heart failure, arrhythmia, stroke, 
transient ischemic attacks, peripheral vascular disease, as well as, hypertension, diabetes, and or 
severe dyslipidemia (defined as plasma triglyceride levels > 6 mmol/L or cholesterol levels > 7 
mmol/L). Smoking and the use of vasoactive medications, such as dietary supplements 
containing vitamins or antioxidants and bronchodilators, also served as exclusion criteria for the 
study participants. In addition, potential subjects were screened for ocular diseases and were 
excluded from if they had a refractive error of more than ±3DS and more than ±1DC equivalent, 
elevated intraocular pressures (> 21 mmHg), retinal disease, intraocular surgery, neuro-
ophthalmic disease, cataract, or other media opacities that may affect the ocular vascular system 
or prevent retinal vascular examination.  
 
 
 
 
 
Page 5 of 26 Acta Ophthalmologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
General assessments 
All study-related measurements were performed between 8 and 11 AM following a 12-hour 
overnight fast, which included refraining from alcohol or caffeine. Standard anthropometric 
measures of height and weight were recorded to determine body mass index (BMI = 
weight/height
2
). Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate 
(HR) were measured using an automatic BP monitor (UA-767; A&D Instruments Ltd, UK) to 
determine mean arterial pressure (MAP = 2/3 DBP + 1/3 SBP). Intraocular pressure (IOP) was 
measured using non-contact tonometry (Pulsair; Keeler Ltd, UK) to determine ocular perfusion 
pressure (OPP = 2/3 MAP – IOP). In addition, blood and plasma samples drawn from the 
antecubital fossa vein were assessed immediately for fasting glucose (GLUC), triglycerides 
(TG), total cholesterol (CHOL), and high-density lipoprotein cholesterol (HDL-c) using the 
Reflotron Desktop Analyzer (Roche Diagnostics, UK). Low-density lipoprotein cholesterol 
(LDL-c) values were calculated as per the Friedewald equation (Friedewald et al. 1972). 
Cardiovascular risk scores for each subject were also calculated using the current version of the 
Framingham risk score (FRS) published by an expert panel of the National Heart, Lung and 
Blood Institute (NHLBI 2002), which includes the following risk factors: age, sex, CHOL, HDL-
c, SBP, treatment for hypertension, smoking status, and diabetes. Age, sex, treatment for 
hypertension, smoking, and the presence of diabetes were identified from self-report 
questionnaires, whereas CHOL, HDL-c, and SBP values were as those determined on the day of 
study. The risk scoring algorithm is based on gender-specific points assigned for each risk factor 
variable. Ten-year risk percentage was then calculated based on total points (1 point, 6%; 2 
points, 8%; 3 points, 10%; 4 points, 12%; 5 points, 16%; 6 points, 20%; 7 points, 25%; 10 points 
or more, > 30%). Finally, the absolute CVD risk percentage was classified as low risk (< 10%), 
intermediate risk (10-20%), or high risk (> 20%) (Ford et al. 2004). Only those individuals 
classified in the low-risk category were considered for this study.  
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Vascular assessments 
Carotid intima-media thickness measurements of the common carotid arteries (c-IMT) were 
obtained for all participants, as described previously (Seshadri et al. 2015), and in accordance 
with an already published protocol (Salonen et al. 1991). Briefly, with the subject in supine 
position, a high-resolution B-mode ultrasound system (Siemens, Acuson-Sequoia, UK) was used 
to capture an image of the right then left carotid artery at the level of the carotid bifurcation. 
Measurements of the thickness of the inner two layers of the artery were then taken from the 
central region of the inferior arterial wall at a site proximal to the artery bifurcation using the 
instrument’s in-built software caliper system.  
Flow-mediated dilation (FMD) of the brachial artery was determined using a high-resolution 
ultrasound imaging system with a 7 mm 8MHz linear-array (Siemens; Acuson-Sequoia, UK). 
The brachial artery was imaged above the antecubital fossa in a longitudinal plane. A segment 
with clear anterior and posterior intimal interfaces between the lumen and vessel wall was 
selected for continuous 2D grey-scale imaging. The vessel diameter,  from the anterior to the 
posterior interface between the media and adventitia, was then continually measured using a  
specialized, artificial neural networking, wall-detection software (VIA
® 
Software, UK). 
According to a published protocol (Corretti et al. 2002), a baseline image of the artery was 
f i r s t  acquired. The brachial artery was then temporarily occluded by BP cuff inflated 50 
mmHg above each individual’s SBP for a standardized five minutes. Image recording was then 
continued for an additional two minutes following cuff deflation. Endothelium-dependent FMD 
(FMDED) was expressed as a percentage of the maximal artery dilation during hyperemia 
(MDhyperemia) relative to the average vessel diameter recorded during the 2-minute baseline image 
acquisition (ADbaseline). 
Dynamic retinal vessel analysis (DVA) was carried out using the retinal vessel analyzer system 
(IMEDOS; GmbH, Jena, Germany). All measurements were performed in one unselected eye 
following full pupil dilation with Tropicamide 1% (Chauvin Pharmaceuticals Ltd, UK), and in a 
quiet, temperature-controlled room (22˚C). A visual fixation target was used to control eye 
movements and to position the region of interest at the center of the fundus image. Within this 
region, a segment approximately 0.5 to 1 mm and 1 to 2 disc diameters from the optic nerve head 
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was selected for continual diameter recording, for both the inferior temporal retinal artery and 
retinal vein. Arterial and venous vessel diameters were then assessed simultaneously and 
continuously over 350 seconds, according to an accepted and widely used protocol (Nagel et al. 
2006). In short, the whole vessel diameter measurement duration (350 seconds) consists of a 50-
second baseline measurement followed by continual diameter recordings during three 
consecutive 100-second flicker cycles, each comprised of 20 seconds of flickering light 
(stimulus) interrupted by 80 seconds of still illumination (recovery). Visualization plots to 
evaluate the dynamic nature of the vessels’ response profiles were created by extracting the raw 
response data from the device software and applying a statistical polynomial regression 
algorithm using MATLAB (Mathworks, USA) according to a method perfected in-house 
(Mroczkowska et al. 2012) The following retinal vessel reactivity and time course parameters 
were then calculated for both the artery and the vein (Heitmar et al. 2010). The differences 
between maximum and minimum baseline vessel diameter was termed as baseline-diameter 
fluctuation (BDF), the maximum diameter (MD) was used to describe the maximal vessel 
dilation in response to flicker-light stimulation expressed as a percentage relative to baseline, the 
time taken (seconds) to reach the maximum vessel diameter during the twenty-second flicker 
exposure was termed as MD reaction time (tMD), the minimal vessel diameter within thirty 
seconds of the recovery period was calculated as a percentage relative to baseline and expressed 
as the maximum constriction (MC) whilst the time taken (seconds) to reach maximal vessel 
constriction was termed maximum constriction reaction time (tMC), and finally, the difference 
between maximal dilation and constriction responses was termed as the dilation amplitude (DA). 
More recently, an additional parameter was introduced by our research group that can be used 
describe the change in vessel diameter as a function of time (slope) and can be calculated for the 
dilation (SlopeD = (MD-baseline)/tMD) and constriction components (SlopeC = (MC-
baseline)/tMC) of the vessel response profile (Mroczkowska et al. 2012). 
Statistical analysis 
All statistical analyses were performed using Statistica
®
 software (Version 9, StatSoft Inc, USA). 
The Shapiro-Wilk test was used to determine the distribution of the data. Multivariate analysis 
was used to test the influence of age, BMI, BP, circulating markers, and systemic parameters on 
the measured variables. Differences between groups were subsequently assessed using 
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independent sample t-tests or ANCOVA, as appropriate. Within-group correlations between 
retinal vascular reactivity and systemic parameters were explored using Pearson’s or Spearman’s 
rank method, as appropriate. A p-value of less than 0.05 was considered significant, except in 
certain cases where a stricter p-value of less than 0.01 was adopted in order to correct for 
multiple comparisons. 
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What is described in the results section is RESULTS 
In total, 102 participants were screened for eligibility of which 27 were excluded on the basis of 
having moderate or high FRS scores (>10%) or if the quality of the DVA recording was below 
the acceptable quality control. The remaining 75 healthy subjects were then classified into one of 
two groups based on the self-declared presence or absence of CVD in a first-degree relative (FH 
positive: n = 38, controls: n = 37, respectively). The number of participants in each group was 
similar (Chi-square p = 0.909) as was the within-group distributions of male (M) and female (F) 
participants (FH positive: M = 20; F = 18, Control: M = 22, F = 15, Chi-square p = 0.551).  
Clinical characteristics 
A summary of the clinical and systemic vascular characteristics of the FH positive and control 
subjects is presented in Table 1. There were no significant group differences in age, BMI, SBP, 
DBP, HR, MAP, IOP, OPP, GLUC, TG, CHOL, LDL-c, TG: HDL-c, and FRS (all p > 0.05). 
However, in comparison to controls, FH positive subjects exhibited lower levels of HDL-c (p = 
0.030) and higher CHOL: HDL-C ratios (p = 0.021). 
Systemic vascular parameters 
After correcting for all the possible influences identified through the multivariate analyses, there 
were no significant group differences in c-IMT scores brachial ADbaseline, MDhyperaemia, or FMDED 
(all p > 0.05 ANCOVA, Table 1)   
Retinal vascular parameters 
Arterial response. After controlling for influential covariates in ANCOVA models, statistically 
significant differences in arterial BDF (p = 0.001), MD% (p = 0.001), MC% (p = 0.008), and 
SlopeAC (p < 0.001) (Fig. 1 A) were identified between the two study groups (Table 2). No 
significant group differences in any of the other measured arterial DVA parameters were 
identified (all p > 0.05).  
Venous response. After controlling for influential covariates in ANCOVA models as 
appropriate, group comparisons showed statistically lower venous BCFR (p = 0.009) and dilation 
Page 10 of 26Acta Ophthalmologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
response SlopeVD (p = 0.010) in the FH positive group in comparison to controls (Table 2; Fig. 
1B). No significant group differences in any of the other measured venous DVA parameters were 
identified (all p > 0.05). 
Correlations between microvascular retinal function and systemic parameters 
In the FH positive group, increased arterial MC% was associated with decreased HDL-c (r = -
0.52, p = 0.002, Fig. 2). A similar trend could not be observed in the control group (p > 0.05). No 
other significant correlations were identified in either of the study groups (p > 0.05). 
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DISCUSSION  
This study has demonstrated that independent of systemic influences, early signs of 
microvascular dysfunction are detectable at the retinal arterial and venous levels of otherwise 
healthy subjects with a positive FH for CVD, even when the macrovascular structure and 
function (as assessed by c-IMT and FMD measurements) are within normal limits. These 
changes correlated with established plasma markers for cardiovascular risk. 
Firstly, spontaneous variations in baseline diameters before the onset of flicker (BDF) were 
found to be reduced in the FH positive subjects in comparison to controls. We can hypothesize 
that this observation is the result of an imbalance in the adaptive mechanism that enables a 
healthy vessel to adjust its baseline diameters to an increased metabolic demand after flickering 
stimulation (Kotliar et al. 2004; Vilser et al. 2002; Kotliar et al. 2011). In addition, a reduction in 
arterial dilation and over-constrictions post-flicker were also observed in individuals with 
positive FH as compared to controls. It is possible that the participants with a positive FH for 
CVD, although otherwise healthy, displayed some limitations in the functional vascular reserves 
that may only be evident after provocative stressors showing that increased challenges cannot be 
met. In addition, we also observed that FH positive subjects demonstrated a decreased retinal 
venous dilation response slope, a composite parameter that could reflect a decrease in retinal 
venous dilation diameter and/or a delay in reaching maximal dilation diameter. Although retinal 
veins are thought to play a more passive role in autoregulatory function (Kotliar et al. 2004) we 
could speculate that the functional changes observed at both arterial and venous levels could 
signal key generalised microvascular alterations associated with the presence of non-modifiable 
risk factors, such as FH. It is possible that such limitation in the retinal vascular function are 
inherited and will predispose individuals with a positive FH to CVD later in life.  
 
Our observations of abnormal retinal microvascular responses in this category of individuals  is 
in line with previous studies reporting  reduced coronary blood flow( Schachinger et al. 1999) 
and skin reactive hyperemia in otherwise healthy subjects with FH of hypertension (Maver et al. 
2004)  or diabetes (Lee et al. 2011)  Moreover, previous studies have also demonstrated that an 
impaired microvascular endothelial function may be evident as early as adolescence in those 
with a FH of cardiovascular disease (de Jongh et al. 2002) . Indeed, poor microvessel function 
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represents an inherited phenotype for CVD risk in patients with familial risk factors (Noon et al. 
1997; Barrett-Connor et al. 1984; Colditz et al. 1986; Marenberg et al. 1994; Friedlander et al. 
1985; Grech et al.1992). 
However, beside genetic factors, other mechanisms could also be contributing to the two above-
mentioned pathological entities
 
(Martino et al. 2015) of circulatory function. Longitudinal, more 
complex studies are, therefore, required to understand the relative importance of our observations 
in FH positive individuals. From our experience, in individuals with low CVD risk, retinal 
microvascular function can be affected by various factors such as ethnicity (Patel et al. 2011) and 
ageing (Seshadri et al. 2015a). In addition, we have also published that body’s antioxidant 
capacity is also linked to the vascular function as measured at the microvascular retinal level 
(Seshadri et al. 2015b). This later observation is very important and could offer us a possible 
explanation for the present findings. Indeed, it has been independently shown that individuals 
with a positive FH for CVD display higher levels of oxidative stress than the normal population
 
(Kelishadi et al. 2009). Although the levels of antioxidant molecules were not determined and 
compared in this study, it can be hypothesized that this factor could have contributed to our 
findings.  
 
Our study also found a favourable relationship between high HDL-C level and microvascular 
function at the retinal arterial level. Indeed, subjects without a positive family history of CVD 
had higher HDL-C levels than those with positive FH and in the latter category, the abnormal 
HDL-C level was associated with an abnormal vascular constriction response. It has been 
previously shown that high levels of HDL-C do not only offer protection against atherosclerosis 
but also predicts a favourable course of symptomatic vascular disease (Kim et al. 2014). 
Therefore, our study comes to confirm the necessity of treating low HDL-C levels in individuals 
without overt CVD but with risk factors such as history of premature CHD (<50 years old in a 
first-degree relative)
 
(Link et al. 2007). 
 
In conclusion, the results of the present study show that familial risk for CVD is associated with 
alterations in retinal vascular function that correlate with circulating markers for CVD risk. With 
traditional cardiovascular risk scoring systems such as the FRS known to severely underestimate 
relative risk (Vasan 2006; Cohn 2013) the findings of the present study suggest that functional 
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retinal assessments can provide an improved diagnostic capability for the detection of subclinical 
microvascular dysfunction. This approach could be promising in furthering the concept of early 
vascular screening and prevention strategies, an important step towards the development of 
individualized and targeted endothelial therapies that can improve the life-time risk in 
individuals that were traditionally considered low-risk
 
(Chia 2016). 
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Figure Legends 
Figure 1. Group comparisons of retinal vascular response profiles. 
(A) Arterial response, (B) Venous response. Abbreviations: AU, arbitrary units; BDF, baseline 
diameter fluctuation; BCFR, baseline corrected flicker response; FH, family history; MD%, 
percent dilation; MC%, percent constriction; SlopeAC, arterial constriction slope; SlopeVD, 
venous dilation slope. 
Figure 2. Correlation between HDL-c and retinal arterial percent constriction in the FH 
positive group. 
Abbreviations: FH, Family history; HDL-c, high-density lipoprotein cholesterol; MC%, percent 
constriction. 
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Table 1. Clinical and systemic vascular characteristics 
 
Variable 
                            Mean (SD) 
p-value Significance 
FH positive (1) Control (2) 
N 38 37 0.909 - 
Gender 20M : 18F 22M : 15F 0.551 - 
Age (years) 47 (11) 45 (11) 0.468 - 
BMI (kg/m
2
) 27.13 (4.45) 26.75 (4.72) 0.727 - 
SBP (mmHg) 121 (11) 121 (12) 0.752 - 
DBP (mmHg) 74 (9) 76 (9) 0.227 - 
HR (bpm) 65 (10) 68 (8) 0.096 - 
MAP 89.36 (8.90) 91.29 (9.05) 0.356 - 
IOP (mmHg) 14 (2) 14 (3) 0.439 - 
OPP 45.15 (6.36) 46.91 (5.54) 0.206 - 
GLUC (mmol/L) 4.95 (1.07) 5.08 (0.58) 0.539 - 
TG (mmol/L) 1.14 (0.44) 1.15 (0.62) 0.958 - 
CHOL (mmol/L) 4.68 (1.02) 4.55 (0.98) 0.578 - 
HDL-C (mmol/L) 1.16 (0.41)* 1.39 (0.45) 0.030* 1 < 2 
LDL-C (mmol/L) 3.00 (0.97) 2.67 (0.92) 0.156 - 
TG/HDL-c 1.11 (0.56) 1.00 (0.84) 0.515 - 
CHOL/HDL-c 4.39 (1.36)* 3.61 (1.36) 0.021* 1 > 2 
FRS % 5.91 (4.16) 4.85 (3.78) 0.105 - 
c-IMT 0.55 (0.11) 0.58 (0.11) 0.318 - 
ADbaseline (mm) 4.16 (0.93) 4.44 (0.88) 0.174 - 
MDhyperaemia (mm) 4.61 (1.12) 5.14 (1.26) 0.060 - 
FMDED 10.88 (9.42) 12.13 (8.63) 0.520 - 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; MAP, mean 
arterial pressure; IOP, intraocular pressure; OPP, ocular perfusion pressure; GLUC, glucose; TG, triglycerides; CHOL, total 
cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; FRS%, Framingham risk 
score; c-IMT, carotid intima media thickness; ADbaseline, brachial baseline diameter; MDhyperaemia, maximum brachial diameter 
during hyperaemia; FMDED, endothelium-dependent flow-mediated dilation. * Significant p-values are indicated in bold where p 
< 0.05 was considered 
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Table 1. Group differences in retinal vascular reactivity parameters 
 
DVA parameter 
                          Mean (SD) p-value 
(t-test/ANCOVA) 
 
Significance FH positive (1) Control (2) 
Arteries:      
Baseline 100.02 (0.05) 100.01 (0.06) 0.552 - 
BDF 5.13 (2.10) 6.50 (2.88) 0.001* 1 < 2 
BCFR 1.04 (2.00) 1.12 (3.07) 0.882 - 
DA 6.16 (2.67) 7.51 (2.76) 0.015 - 
MD% 3.74 (2.25) 5.22 (2.50) 0.001* 1 < 2 
MC% -2.42 (1.87) -2.29 (2.31) 0.008* 1 > 2 
tMD (seconds) 19 (6) 22 (8) 0.048 - 
tMC(seconds) 29 (6) 26 (8) 0.064 - 
SlopeAD 0.24 (0.12) 0.30 (0.15) 0.070 - 
SlopeAC -0.25 (0.13) -0.38 (0.25) <0.001* 1 < 2 
      
Veins:   
   
Baseline 100.00 (0.04) 100.00 (0.03) 0.775 - 
BDF 3.94 (1.78) 3.79 (1.68) 0.011 - 
BCFR 1.40 (2.42) 2.35 (1.83) 0.009* 1 < 2 
DA 5.33 (2.91) 6.09 (2.60) 0.242 - 
MD% 4.44 (2.74) 5.43 (2.38) 0.045 - 
MC% -0.90 (1.59) -0.66 (1.04) 0.461 - 
tMD (seconds) 21 (6) 20 (4) 0.200 - 
tMC (seconds) 28 (7) 31 (8) 0.058 - 
SlopeVD 0.23 (0.13) 0.29 (0.12) 0.010* 1 < 2 
SlopeVC -0.23 (0.16) -0.23 (0.14) 0.960 - 
Abbreviations: Baseline, average baseline diameter: BDF, baseline diameter fluctuation; DA, dilation amplitude; BCFR, baseline corrected 
flicker response; MD%, percent dilation (during flicker); MC%, percent constriction (post-flicker); tMD, time taken to reach maximal dilation 
(MD) diameter; tMC, time taken to reach maximal constriction (MC) diameter; SlopeAD/VD, slope of arterial/venous dilation; SlopeAC/VC, slope of 
arterial/venous constriction. *Significant p-values are indicated in bold where p < 0.01 was considered significant 
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